Efficacy of Lamivudine Combined with Thymosin ?_1 on Young Patients with Chronic Hepatitis B
- VernacularTitle:胸腺素?_1联合拉米夫定治疗慢性乙型肝炎
- Author:
ya-li, LI
;
li- hua, li, ZHANG
;
qiu-zheng, CHEN
- Publication Type:Journal Article
- Keywords:
thymosin ?1;
lamivudine;
chronic hepatitis B
- From:Journal of Applied Clinical Pediatrics
1992;0(05):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy of lamivudine( LAM) combined with thymosin ?1 (T?1) on young patients with chronic hepatitis B. Methods Sixty six chronic hepatitis B (CHB) patients aged from 12 to 16 years and weight greater than 33 kg were divided into the LAM + T?1 group and the LAM group; in LAM + T?1 group,T?1 was administered 1.6 mg hypodermic once daily and after 5 days it was changed to 1 6 mg hypodermic, twice in two weeks, and the drug was stopped after 26 weeks, while LAM had been administered 100 mg each time once daily for 52 weeks. In LAM group, only LAM had been administered 100 mg once daily for 52 weeks. The serum level of HBV DNA, HBV markers and the ALT were measured before and after treatment Results After the treatment, the rate of serum HBV UNA turned to negative in LAM + T?1 group was 100 % , and that in LAM group was 93.7 % ; recovery ratios at 52 weeks of LAM+ T?1 group was 87.1% ,and that of LAM group was 78. 1% .After 52 weeks, the HBeAg serum conversion rate of LAM + T?1 group was 58. 1 % , and that of the LAM group was 21.9%. Comparing the results of the two groups, the difference was remarkable. Conclusion The efficacy of T?1 combined with LAM on young patients with chronic hepatitis B is superior to that use of single LAM
